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DOI 10.1016/j.chembiol.2008.02.002If you are the sum of accumulated experi-
ences, then Alzheimer’s disease is the ul-
timate thief. The most common of a group
of age-related dementias, Alzheimer’s
disease disrupts the neural system, eras-
ing memories or causing patients to re-
member things that never happened,
changing personality, and destroying the
ability to communicate and function
before it kills. Alzheimer’s disease (AD)
affects over 5 million Americans and an
estimated 26 million people worldwide.
In 1906, Dr. Alois Alzheimer, a German
physician, described the case of Auguste
D., a 51 year old patient who suffered mys-
terious memory loss, disorientation, and
odd behavior. Upon her death, Alzheimer
autopsied her and discovered that her
brain had atrophied. He also found patho-
logical amyloid plaques and neurofibrillary
tangles in her brain, but he could not tell
whether they were a symptom of her dis-
order or the cause.
A century later, much about Alzheimer’s
disease remains an enigma. Most re-
searchers now accept that it is the amyloid
b-protein (Ab) which forms the plaques
and fibrils in the Alzheimer’s brain that
disrupts and kills neurons or triggers a
cascade of events that lead to neuronal
death. Exactly how Ab wreaks its havoc
is controversial. ‘‘We have opinions, but
nothing we can put in a textbook,’’ says
Dr. David Teplow, professor of neurology
at the David Geffen School of Medicine
at UCLA.
Four FDA-approved therapies, Aricept,
Excelon, Reminyl, and Cognex, are ace-
tylcholinesterase inhibitors. A fifth drug,
Namenda, a NMDA receptor antagonist,
acts on the glutamatergic neurotransmit-
ter system involved in memory formation
and information processing. However,
these drugs only help by increasing syn-
aptic communication. ‘‘It is as if you are
giving aspirin to somebody with pneumo-
nia,’’ said Gal Bitan, Ph.D., assistant pro-
fessor of neurology at the David Geffen
School of Medicine, UCLA. ‘‘These drugs
help moderately and temporarily but do
not prevent the cause of the disease.’’
Some researchers hypothesize that by
the time symptoms appear, the disease
has been in progress for 15 years or so,
but diagnoses based on biomarkers have
emerged only recently. Ab, a 40–42 amino
acid, is produced in the brains of healthy
people and its role is unknown. Normally,
Ab is cleaved from an amyloid precursor
protein (APP) by b and g secretase en-
zymes and further metabolized. But in
AD, the Ab accumulates and self assem-
bles, first into soluble oligomers and then
into insoluble plaques in the brain, causing
nerve injury, inflammation, and cholinergic
deficits that impair nerve communication
and eventually destroy neurons.
According to Bitan, soluble Ab oligo-
mers are the proximal causes of these in-
sults and later go on to form the offending
fibrils and plaques. ‘‘So what we believe
today, what happens in Alzheimer’s, is
that in the very early stages, these oligo-
mers—even before they kill the neu-
rons—disrupt their ability to talk with
each other,’’ said Bitan. ‘‘And therefore
you lose your memory.’’
Loitering in Risky Genetic
Neighborhoods
AD stems from the interplay of heredity
and lifestyle. A form of aggressive, early-
onset AD that strikes less than 1% of
people before age 65 is attributed to mu-
tations in the amyloid precursor protein
(APP) and presenilin-1 and presenilin-2
genes.
But for most people, getting old is the
main factor that raises risk for AD, as
well as prior head trauma and a history
of depression. The common apolipopro-
tein E (ApoE) gene, which is located on
chromosome 19 and involved in lipid and
triglyceride transport, is implicated in AD.
One allele in particular, 34, raises the risk
of developing Alzheimer’s disease 3-fold
over the general population if you have
one copy, and 15-fold if you have two.
‘‘There are a lot of diseases that have
a genetic component, but in many of
them, if not most of them, the genetic
component causes only a minority of the
cases,’’ said Teplow. ‘‘The major caseload
comes from nongenetic reasons or at least
genetic reasons that have not been identi-
fied yet. It is true in Alzheimer’s disease. It
is true in the prion diseases. It is true in
amyotrophic lateral sclerosis (ALS). It is
true in Parkinson’s. All these neurodegen-
erative diseases are diseases of aging,
and the minority of them are caused by
identifiable genetic changes. So Ab may
or may not be the cause.’’
New drugs inching closer to the clinic
promise to delay or stop the progression
of the disease, but there is no single
path forward. A number of companies, in-
cluding Myriad, Wyeth, Elan, and Glaxo,
have compounds in phase III testing that
either block the production of Ab, attempt
to eliminate fibrils, or affect assembly of
existing Ab.
Blocking Amyloid Production
South San Francisco/Oklahoma City-
based CoMentis (http://www.comentis.
com) is developing a b secretase inhibitor,
CTS-21166, which has just finished phase
I trials.
‘‘Our company is targeting one of the
most attractive targets, the b secretase
enzyme, in the brain and coming up with
an inhibitor of that enzyme would reduce
the production of Ab 40–42.’’ said Dr. W.
Scott Harkonen, president and CEO of
CoMentis. According to Harkonen, b sec-
retase is a ‘‘pretty clean target,’’ but g
secretase is associated with more serious
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small-molecule drug using crystallogra-
phy-based rational drug design. Scientific
founders Jordan Tang, Ph.D. and col-
leagues at Oklahoma Medical Research
Foundation and Arun Ghosh, Ph.D., now
at Purdue University, were among the first
to isolate the secretases and developed
the first inhibitor of b secretase. ‘‘We’ve
been able to come up with a family of
orally available compounds that get into
the brain and have single-digit nanomolar
potency,’’ said Harkonen.
‘‘The problem is that with some of these
inhibitors, especially the g inhibitors, is
that g secretase not only cuts APP but
other molecules as well,’’ said Teplow.
‘‘If you inhibit this enzyme, you can poten-
tially get other significant side effects.’’
Perhaps the furthest along is Myriad
Pharmaceutical’s (http://www.myriad.
com) Flurizan, a g secretase modulator
now in dual phase III trials for patients
with mild Alzheimer’s disease. Flurizan is
a selective amyloid-lowering agent
(SALA). The drug so far has lowered levels
of Ab 42 in vitro and in animals.
‘‘On Flurizan, there is a debate as to
whether it will be potent enough to really
make a difference in slowing Alzheimer’s
symptoms,’’ said Dr. Dennis Selkoe,
Coates Professor of Neurology at Harvard
Medical School and codirector of the
Center for Neurologic Diseases at Brig-
ham and Women’s Hospital. Selkoe was
a founding scientist of Athena Neurosci-
ences, now Elan Pharmaceuticals (http://
www.elan.com). ‘‘My view is that it might
be. I think the way they’ve designed the
trial is very good. I think we will know
mid-2008 or a little later whether it has
had a clinical benefit or not.’’
Preventing Assembly
Toronto-based Transition Therapeutics
(http://www.transitiontherapeutics.com)
has a codevelopment deal with Elan worth
potentially $200 million in milestone pay-90 Chemistry & Biology 15, February 2008 ªments ($15 million upfront) for its oral
small-molecule drug ELND005 (formerly
AZD-103). Its compound, a scyllo-inositol,
received fast-track designation from the
FDA. ‘‘The idea with this compound is
that it can be preventative if you can get
it early enough to prevent those fibrils
from forming, but if you have existing
fibrils, it can break those fibrils down,’’
said Dr. Tony Cruz, Transition Therapeu-
tics CEO. According to Cruz, the com-
pound enters the brain via the myo-inositol
transporter. So far, it has increased sur-
vival in transgenic animal models. ‘‘It has
a very good safety profile, so we can go
at very high doses in humans without
fear of major adverse events.’’ Elan and
Transition are currently enrolling 340 pa-
tients with mild-to-moderate Alzheimer’s
disease in an 18 month phase II efficacy
trial in North America. ‘‘It is a natural prod-
uct,’’ said Dennis Selkoe. ‘‘But it has to be
given in very high doses in order to achieve
useful brain levels. So one doesn’t yet
know if it is going to be efficacious
enough.’’
The compound was licensed from the
work of Professor JoAnne McLaurin and
colleagues at the Centre for Research in
Neurodegenerative Diseases at the Uni-
versity of Toronto, who identified a small
molecule, scyllo-cyclohexanehexol, that
prevented the Ab peptide from aggregat-
ing in fibrils by stabilizing it in a low molec-
ular weight.
Clearing Out Amyloid Proteins
Elan and Wyeth’s AAB-001(Bapineuzu-
mab) is a humanized monoclonal anti-Ab
antibody intended to bind and remove
the Ab peptide that accumulates in the
brain. This vaccine is based on the work
of Dale Schenk, Ph.D., executive vice
president at Elan. The company is enroll-
ing 41,000 patients in North America and
Europe in a phase III clinical test overlap-
ping with a phase II study. The trial will
have four arms; two of those will be com-2008 Elsevier Ltd All rights reservedprised of people who possess the APO34
allele and two will comprise people who
do not. ‘‘I think this is the first actual trial
where a specific genotype is the basis
for putting people into two parallel trials,’’
said Selkoe. According to Selkoe, it is
possible that the drug will work better in
people without the APO34 variants be-
cause they have a less aggressive form
of Alzheimer’s and tend not have as
much vascular amyloid. Eli Lilly also has
a competitive antibody in phase II and
a more traditional g secretase inhibitor.
More Questions than Answers
Elan is also actively vaccinating Alz-
heimer’s patients with an Ab peptide. The
original idea of using the immune system
to fight Alzheimer’s disease came from
Professor Beka Solomon’s lab at Tel Aviv
University. Vaccinating transgenic mice
against components of human amyloid
showed Ab clearance and recovery of
memory, but Elan and Wyeth aborted
a phase II human trial of AN 1792 in 2002
when 6% of patients developed autoim-
mune encephalitis, a severe inflammation
of the brain. ‘‘There was a correlation with
their antibody titers and their mental sta-
tus,’’ said Selkoe. ‘‘The earlier active vac-
cine will never be used again, but Elan
and Wyeth are developing a truncated Ab
peptide without the t-cell epitope, ACC-
001, now in phase II.’’
David Teplow often refers to a comment
made to his wife, Arden, a clinical thera-
pist, by an early stage Alzheimer patient
who described her increasing confusion
as ‘‘I don’t know what I know.’’ Teplow
says, ‘‘And that is just a chilling comment
for me and for other people also. It reflects
part of the clinical presentation which
causes quite tremendous anxiety in the
early stages of the disease. It is that sense
of cognitive disorientation that is really
very devastating to many people.’’
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